Author:
Mahner Sven,Oskay-Özcelik Gülten,Heidrich-Lorsbach Elke,Fuxius Stefan,Sommer Harald,Klare Peter,Belau Antje,Ruhmland Birgit,Heuser Thomas,Kölbl Heinz,Markmann Susanne,Sehouli Jalid
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference18 articles.
1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds) (2010) SEER Cancer Statistics Review, 1975–2007. National Cancer Institute, Bethesda. http://seer.cancer.gov/csr/1975_2007/ , based on November 2009 SEER data submission, posted to the SEER web site, 2010
2. Breidenbach M, Rein DT, Schöndorf T, Schmidt T, König E, Valter M, Kurbacher CM (2003) Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer. Anticancer Drugs 14:341–346
3. Gondos A, Holleczek B, Arndt V, Stegmaier C, Ziegler H, Brenner H (2007) Trends in population-based cancer survival in Germany; to what extent does progress reach older patients? Ann Oncol 18:1253–1259
4. Gropp M, Meier W, Hepp H (1998) Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol 71:94–98
5. Harter P, du Bois A, Schade-Brittinger C, Burges A, Wollschlaeger K, Gropp M, Schmalfeldt B, Huober J, Staehle A, Pfisterer J (2005) Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Ann Oncol 16:1801–1805
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献